Apyx Medical Inc

Apyx Medical Inc(APYX)の株式分析

$3.060

+0.555 (+18.15%)終値時点

Loading chart…
高値
3.107
始値
2.600
出来高加重平均価格
2.91
出来高
995.02K
時価総額
48.85M
安値
2.575
売買代金
2.90M
EV/EBITDA(TTM)
-15.53

Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs.

apyxmedical.com

AI分析 of Apyx Medical Inc (APYX)

買い

Apyx Medical Corp appears to be a good buy right now, trading at $2.60 with a recent RSI of 56.79, indicating a balanced momentum. The forward P/E ratio is quite high at 72.46, suggesting that while the stock may be overvalued in the short term, the growth potential is significant. The stock has shown a 5.69% increase over the past five days, indicating positive short-term momentum. Furthermore, Maxim Group's buy rating reflects confidence in the company's innovative technology and growth potential, particularly as they raised their revenue guidance for 2026 to between $59 million and $60 million. However, the main risk is the negative net income, which was -$3.24 million in Q2 2026, indicating ongoing losses that investors should monitor closely.

バリュエーション指標

Apyx Medical Inc(APYX)の現在の予想PERは72.46で、5年平均は5.82です。

予想PER

大幅な割高
5年平均 P/E
5.82
現在のP/E
72.46
割高
36.80
割安
-25.16

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-9.40
現在のEV/EBITDA
-15.53
割高
30.40
割安
-49.21

予想PSR

適正
5年平均 P/S
2.49
現在のP/S
1.65
割高
4.41
割安
0.56

Alphio AI による APYX の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%APYX

$1.80

シナリオ価格

基

基本

基本 · 50%APYX

$1.74

シナリオ価格

弱

弱気

弱気 · 25%APYX

$1.70

シナリオ価格

APYX を保有するクジラ

N

Nantahala Capital Management, LLC

+ を保有APYX

+10.21%

3か月リターン

イベントタイムライン

2026-11-05 (ET)

08:31:00

AYON Reports Q3 Revenue of $14.03M, 17% Growth

08:31:00

Company Expects Gross Margins of 63% to 65%

2026-09-29 (ET)

08:30:00

Apyx Medical Releases Renuvion Study Results, Significant Skin Quality Improvement

2026-08-06 (ET)

17:00:00

AYON Reports Q2 Revenue of $13.88M, Beating Expectations

17:00:00

Company Expects Operating Expenses Below $45 Million for 2026

ニュース

APYX のよくある質問 — Alphio AI が回答

Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Apyx Medical Corp appears to be a good buy right now, trading at $2.60 with a recent RSI of 56.79, indicating a balanced momentum. The forward P/E ratio is quite high at 72.46, suggesting that while the stock may be overvalued in the short term, the growth potential is significant. The stock has shown a 5.69% increase over the past five days, indicating positive short-term momentum. Furthermore, Maxim Group's buy rating reflects confidence in the company's innovative technology and growth potential, particularly as they raised their revenue guidance for 2026 to between $59 million and $60 million. However, the main risk is the negative net income, which was -$3.24 million in Q2 2026, indicating ongoing losses that investors should monitor closely.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める